Patents Assigned to Prothena Biosciences Limited
  • Antibodies recognizing tau
    Patent number: 11958896
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: April 16, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Robin Barbour, Svetlana Alexander, Mark Renz, Shuning Gai, Tarlochan S. Nijjar, Philip James Dolan, III, Philip Payne
  • Antibodies recognizing tau
    Patent number: 11926659
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: March 12, 2024
    Assignee: Prothena Biosciences Limited
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • METHODS OF USING ANTIBODIES RECOGNIZING TAU
    Publication number: 20240018226
    Abstract: The invention provides methods of treating taupathies such as Alzheimer's disease with antibodies that bind to human tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: August 28, 2023
    Publication date: January 18, 2024
    Applicant: Prothena Biosciences Limited
    Inventor: Philip James Dolan, III
  • Tau Immunotherapy
    Publication number: 20230340094
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: April 21, 2023
    Publication date: October 26, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • METHODS OF TREATING AL AMYLOIDOSIS
    Publication number: 20230331831
    Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
    Type: Application
    Filed: May 8, 2023
    Publication date: October 19, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Gene Kinney, Wagner Marcelo Zago, Carol Karp, Radhika Tripuraneni
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20230250161
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 17, 2023
    Publication date: August 10, 2023
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Methods of treating AL amyloidosis
    Patent number: 11692024
    Abstract: Antibody formulations and methods useful for treatment of patients with AL amyloidosis.
    Type: Grant
    Filed: March 5, 2020
    Date of Patent: July 4, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Gene Kinney, Carol Karp, Wagner Marcelo Zago, Radhika Tripuraneni
  • Tau immunotherapy
    Patent number: 11643457
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: October 29, 2019
    Date of Patent: May 9, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Antibodies recognizing tau
    Patent number: 11584791
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: February 21, 2023
    Assignee: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220372118
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: November 24, 2022
    Applicant: Prothena Biosciences Limited
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220275067
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 7, 2020
    Publication date: September 1, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Philip James DOLAN, III, Tarlochan S. NIJJAR, Svetlana ALEXANDER, Robin BARBOUR, Stephen Jed TAM
  • Humanized antibodies that recognize alpha-synuclein
    Patent number: 11345749
    Abstract: The present application discloses humanized 9E4 antibodies. The antibodies bind to human alpha synuclein and can be used for immunotherapy of Lewy body disease.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: May 31, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Jose William Saldanha, Tarlochan S. Nijjar
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20220089702
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2018
    Publication date: March 24, 2022
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Svetlana ALEXANDER, Mark RENZ, Shuning GAI, Tarlochan S. NIJJAR, Philip James DOLAN, III, Philip PAYNE
  • Infrared assay detecting secondary structure profiles of alpha-synuclein
    Patent number: 11237176
    Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: February 1, 2022
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventor: Robin Barbour
  • Monitoring immunotherapy of Lewy body disease from constipation symptoms
    Patent number: 11191832
    Abstract: The invention provides methods of monitoring immunotherapy directed against alpha-synuclein by comparing a subject's constipation symptoms before treatment and at one or more times during and/or after treatment. The immunotherapeutic regime can be monitored depending on the results of treatment.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: December 7, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Gene G. Kinney, Theresa Anne Neumann, Daniel Keith Ness
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20210261652
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 26, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin BARBOUR, Philip James DOLAN, III, Yue LIU, Svetlana ALEXANDER, Mark E. RENZ
  • Anti-transthyretin antibodies
    Patent number: 11028158
    Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: June 8, 2021
    Assignees: Prothena Biosciences Limited, University Health Network
    Inventors: Yue Liu, Tarlochan S. Nijjar, Avijit Chakrabartty, Jeffrey N. Higaki
  • ANTIBODIES RECOGNIZING TAU
    Publication number: 20210130449
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: November 4, 2020
    Publication date: May 6, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Antibodies recognizing tau
    Patent number: 10961302
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: March 30, 2021
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Tarlochan S. Nijjar, Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Antibody Formulations and Methods
    Publication number: 20210077407
    Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.
    Type: Application
    Filed: June 23, 2020
    Publication date: March 18, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Patrick GARIDEL, Isaac Craig HENDERSON, Pamela KLEIN